| __timestamp | BioMarin Pharmaceutical Inc. | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 9079000 |
| Thursday, January 1, 2015 | 402271000 | 20309000 |
| Friday, January 1, 2016 | 476593000 | 16945000 |
| Sunday, January 1, 2017 | 554336000 | 20559000 |
| Monday, January 1, 2018 | 604353000 | 29641000 |
| Tuesday, January 1, 2019 | 680924000 | 88258000 |
| Wednesday, January 1, 2020 | 737669000 | 162170000 |
| Friday, January 1, 2021 | 759375000 | 167218000 |
| Saturday, January 1, 2022 | 854009000 | 239528000 |
| Sunday, January 1, 2023 | 937300000 | 94252000 |
| Monday, January 1, 2024 | 1009025000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. BioMarin Pharmaceutical Inc. and Galapagos NV, two prominent players, offer a fascinating study in contrasts. Over the past decade, BioMarin's SG&A expenses have surged by over 200%, reflecting its aggressive expansion strategy. In 2014, BioMarin's expenses were approximately 300 million, but by 2023, they had tripled, reaching nearly 940 million. Meanwhile, Galapagos NV, starting with a modest 9 million in 2014, saw its SG&A expenses peak at 240 million in 2022, before dropping to 94 million in 2023. This fluctuation suggests a strategic pivot or cost optimization. As these companies navigate the biotech landscape, their SG&A efficiency will be pivotal in determining their competitive edge and long-term sustainability.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Galapagos NV
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Galapagos NV
Gilead Sciences, Inc. or BioMarin Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of GSK plc and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Biogen Inc. vs BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs BioMarin Pharmaceutical Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Comparing SG&A Expenses: Xenon Pharmaceuticals Inc. vs Galapagos NV Trends and Insights
Who Optimizes SG&A Costs Better? Protagonist Therapeutics, Inc. or Galapagos NV
Who Optimizes SG&A Costs Better? Taro Pharmaceutical Industries Ltd. or Galapagos NV